Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNs

November 25th 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Ruxolitinib Is Linked With High Spleen Responses in IPSS Low-Risk Myelofibrosis

November 25th 2020

November 25, 2020 — Ruxolitinib, when administered earlier on in the treatment course, led to high spleen response rates in patients with low-risk International Prognostic Scoring System myelofibrosis.

Idasanutlin Promotes Transient Expansion of TP53-Mutant Subclones in Polycythemia Vera

November 25th 2020

November 25, 2020 - The oral MDM2 antagonist idasanutlin was found to promote expansion of TP53-mutant subclones among patients with polycythemia vera.

Dr. Mascarenhas on the Significance of Pacritinib in Myelofibrosis

November 24th 2020

John O. Mascarenhas, MD, discusses the potential significance of pacritinib in patients with myelofibrosis.

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

JAK Inhibitors Continue to Shape Myelofibrosis Paradigm

November 23rd 2020

 John O. Mascarenhas, MD, discusses how the positioning of JAK inhibitors in myelofibrosis has shifted, and also pointed to new agents under investigation.

Dr. Mascarenhas on Emerging Agents in Myelofibrosis

November 23rd 2020

John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.

Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis

November 19th 2020

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.

Dr. El Chaer on the Limitations of JAK Inhibitors in Myelofibrosis

November 17th 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

New Strategies Improve Outcomes for Lower-Risk MDS

November 4th 2020

Myelodysplastic syndrome is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.

Dr. Mascarenhas on Limitations With JAK Inhibitors in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Masarova on Future Research in MPNs

October 19th 2020

Lucia Masarova, MD, discusses future research efforts in myeloproliferative neoplasms.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Nazha Navigates Emerging Approaches for Polycythemia Vera Post Hydroxyurea

October 16th 2020

Aziz Nazha, MD, discusses risk stratification in polycythemia vera, options that have emerged for patients, approaches to consider following hydroxyurea, and the need for agents that will reverse fibrosis in the bone marrow.

Dr. Bose on Current Treatment Options for Essential Thrombocythemia

October 15th 2020

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia Vera

October 14th 2020

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.